News Sentiment

PDSB sentiment intelligence

PDS Biotechnology Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.77 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

76/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-9.3% over one week, -26.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 76/100 classification
One-week reaction -9.3% Price reacting lower
Trend fit Trend inactive -26.3% over four weeks
Fair value -69.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 37
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 14
Market source 8
Stock Titan 6
Quiver Quantitative 4
simplywall.st 3
Zacks Investment Research 2
Quantisnow 1
TradingKey 1

Event Lens

What the news is about

Classified themes
Earnings 24
Market update 20
Analyst action 4
Deals and strategy 1
Guidance 1
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-52 of 52
ChartMill Direct company coverage

PDS Biotech (NASDAQ:PDSB) Posts Narrower Q1 Loss, Pre-Market Rises Over 5%

PDS Biotech (NASDAQ:PDSB) reported a narrower-than-expected Q1 2026 net loss of -$0.13 per share, beating analyst estimates of -$0.153, while revenue remained zero. The stock reacted positively in pre-market trading, rising over 5%, as investors focused on the clinical milestones

Tone
Positive 66/100
Event
Earnings
Published
13 May 2026 12:10
Source
ChartMill
kens5.com Direct company coverage

PDS Biotechnology: Q1 Earnings Snapshot

PDS Biotechnology Corporation (PDSB) reported a first-quarter loss of $7.3 million, translating to a loss of 13 cents per share. This financial snapshot was generated using data from Zacks Investment Research.

Tone
Negative 30/100
Event
Earnings
Published
13 May 2026 11:39
Source
kens5.com
TradingView Direct company coverage

PDS Biotechnology reports Q1 2026 net loss $7.3M, cash $21.7M; clinical updates on PDS0101 and PDS01ADC

PDS Biotechnology reported a net loss of $7.3 million for Q1 2026 with $21.7 million in cash and cash equivalents. The company also announced significant clinical progress, including an amended Phase 3 protocol for its VERSATILE-003 trial to potentially accelerate approval for PD

Tone
Positive 64/100
Event
Regulatory and legal
Published
13 May 2026 11:10
Source
TradingView
Stock Titan Direct company coverage

PDS Biotech (Nasdaq: PDSB) trims Q1 loss as R&D spending falls

PDS Biotechnology reported a narrowed net loss of $7.3 million in Q1 2026, an improvement from $8.5 million in Q1 2025, primarily due to reduced research and development expenses. The company also provided updates on its clinical pipeline, including progress on the VERSATILE-003

Tone
Neutral 50/100
Event
Market update
Published
13 May 2026 11:10
Source
Stock Titan